Lecture time

November 29, 2025 10:00-11:00

Lecture location

Conference Room 3-117, Building 3, Jinfeng Laboratory

Lecture title: Nanodrug design for inflammatory diseases inspired by clinical problems

Introduction to the speaker

Li Heran , associate professor, doctoral supervisor. Outstanding Youth of Liaoning Province, Hundreds and Thousands of Talents Project of Liaoning Province, Outstanding Graduates of Liaoning Province, Leading Talents of Shenyang City, Outstanding Scientific and Technological Workers of China Medical University, Outstanding Teachers, Young Top-notch Talents, Young Talents, and Youth May Fourth Medal Winners. Focusing on the intersection of chemistry, medicine and pharmacy, the main research directions are the construction of intelligent drug delivery systems and nanomedicine. Hosted 14 top-level scientific research projects of the National Natural Science Foundation of China. In the past five years, he has published 40 SCI papers as the corresponding author in journals such as Nature communications, Advanced Materials, ACS Nano, and Hepatology, with a total impact factor of more than 420, including 30 papers in the first area of ​​the Chinese Academy of Sciences, 10 patent applications, 4 approved, and 1 transformation. He serves as a young editorial board member of journals such as Acta Pharm Sin B, Asian J Pharm Sci, and Nano research, serves as a reviewer for more than 10 journals, serves as a technical consultant and training instructor for 5 companies including Nanjing Hairong Pharmaceutical, and participated in the completion of 4 drugs that passed the consistency evaluation.

Lecture Introduction

During the occurrence and development of inflammatory bowel disease (IBD), driven by genetic, immune, and microbial factors, the main upstream pathogenic factors of IBD, such as lipopolysaccharide (LPS), reactive oxygen species (ROS), and extracellular free DNA (cfDNA), are connected in series with each other in a vicious cycle, triggering a pro-inflammatory signaling cascade, mediating the production of inflammatory factors, and causing damage to the intestine through multiple pathways. A "drug-free" treatment strategy, by simulating the biosilicification reaction under natural environmental conditions, a polyethylenimine-tartaric acid composite template-catalyzed mesoporous organic silica chiral nanomedicine (PEI-L/D-TA@MON) was constructed in a very short time (a few seconds). Chiral nanomedicines include four functional parts, among which PEI electrostatically attracts cfDNA, tetrasulfide bonds consume ROS through redox reactions, silanol groups physically adsorb LPS, and L/D-TA can achieve chiral recognition and inflammation localization. After oral administration, the dominant conformation PEI-L-TA@MON is three-dimensionally matched with the mucosa and anchored to the inflammatory intestine through electrostatic interaction to target the diseased site. PEI-L-TA@MON eliminates LPS, ROS and cfDNA in the inflammatory microenvironment, reduces oxidative stress, inhibits the inflammatory cascade, maintains immune homeostasis, and achieves efficient treatment of IBD. In addition, PEI-L-TA@MON has fast synthesis speed, low cost, no energy requirement for preparation, low toxicity, good therapeutic effect, and easy conversion of treatment modes. It will bring changes to IBD treatment and has important research value and clinical translation prospects.

Everyone is welcome to actively participate